Skip to main navigation Skip to search Skip to main content

Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland

  • Thomas M. Caparrotta
  • , Luke A. K. Blackbourn
  • , Stuart J. McGurnaghan
  • , John Chalmers
  • , Robert Lindsay
  • , Rory McCrimmon
  • , John McKnight
  • , Sarah Wild
  • , John R. Petrie
  • , Sam Philip
  • , Paul M. McKeigue
  • , David J. Webb
  • , Naveed Sattar
  • , Helen M. Colhoun (Lead / Corresponding author)
  • , Scottish Diabetes Research Network Epidemiology Group

    Research output: Contribution to journal › Article › peer-review

    17   Link opens in a new tab Citations (Scopus)
    172 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland'. Together they form a unique fingerprint.
    Sort by

    Medicine and Dentistry

    Keyphrases